Trial · NCT02964507
Adverse events808
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 808
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Phase I- GSK525762 60mg+FUL 500mg (AI Failure) | 12 | 33 | 17 |
| other | Nausea | Gastrointestinal disorders | Phase I-GSK525762 60mg+FUL 500mg (CDK4/6+AI Failure < 12M) | 7 | 12 | 10 |
| other | Nausea | Gastrointestinal disorders | Phase I-GSK525762 60mg+FUL 500mg (CDK4/6+AI Failure >=12M) | 30 | 42 | 38 |
| other | Nausea | Gastrointestinal disorders | Phase I-GSK525762 60mg+FUL 500mg (CDK4/6+AI Failure >=12M Bone Only Disease | 5 | 7 | 9 |
| other | Nausea | Gastrointestinal disorders | Phase I-GSK525762 80mg+FUL 500mg (AI Failure) | 11 | 18 | 21 |
| other | Nausea | Gastrointestinal disorders | Phase I-GSK525762 80mg+FUL 500mg (CDK4/6+AI Failure) | 9 | 11 | 9 |
| other | Nausea | Gastrointestinal disorders | Phase II-GSK525762 +FUL | 0 | 0 | 0 |
| other | Nausea | Gastrointestinal disorders | Phase II-Placebo+FUL | 0 | 0 | 0 |
| other | Fatigue | General disorders | Phase I- GSK525762 60mg+FUL 500mg (AI Failure) | 19 | 33 | 24 |
| other | Fatigue | General disorders | Phase I-GSK525762 60mg+FUL 500mg (CDK4/6+AI Failure < 12M) | 4 | 12 | 6 |
| other | Fatigue | General disorders | Phase I-GSK525762 60mg+FUL 500mg (CDK4/6+AI Failure >=12M) | 25 | 42 | 38 |
| other | Fatigue | General disorders | Phase I-GSK525762 60mg+FUL 500mg (CDK4/6+AI Failure >=12M Bone Only Disease | 1 | 7 | 1 |
| other | Fatigue | General disorders | Phase I-GSK525762 80mg+FUL 500mg (AI Failure) | 9 | 18 | 12 |
| other | Fatigue | General disorders | Phase I-GSK525762 80mg+FUL 500mg (CDK4/6+AI Failure) | 7 | 11 | 10 |
| other | Fatigue | General disorders | Phase II-GSK525762 +FUL | 0 | 0 | 0 |
| other | Fatigue | General disorders | Phase II-Placebo+FUL | 0 | 0 | 0 |
| other | Dysgeusia | Nervous system disorders | Phase I- GSK525762 60mg+FUL 500mg (AI Failure) | 14 | 33 | 16 |
| other | Dysgeusia | Nervous system disorders | Phase I-GSK525762 60mg+FUL 500mg (CDK4/6+AI Failure < 12M) | 2 | 12 | 3 |
| other | Dysgeusia | Nervous system disorders | Phase I-GSK525762 60mg+FUL 500mg (CDK4/6+AI Failure >=12M) | 25 | 42 | 30 |
| other | Dysgeusia | Nervous system disorders | Phase I-GSK525762 60mg+FUL 500mg (CDK4/6+AI Failure >=12M Bone Only Disease | 4 | 7 | 4 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02964507/events